Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 424 participants, all of whom received the medication adalimumab. Of those, 239 people completed the study and 185 did not finish. The trial was primarily focused on monitoring safety-related measurements — specifically, tracking any medical events that occurred during the study, checking blood test results for notable changes, and recording basic body readings such as heart rate, breathing rate, and temperature. The reported data shows that out of 424 participants, 398 experienced at least one adverse event (an unexpected medical occurrence during the study period), and 101 experienced a serious adverse event (a more significant medical occurrence, such as one requiring hospitalisation or considered life-threatening — though these are not necessarily caused by the medication). For blood test results, small numbers of participants showed values that were flagged as potentially significant: in blood cell counts, the reported figures were 3, 6, and 7 participants across different measures; in chemistry (organ-related) blood tests, the numbers ranged from 1 to 18 participants across eleven different measurements. For physical readings, the reported data shows that average heart rate changed by minus 1.0 beat per minute from the start to the end of the study, breathing rate changed by minus 0.1 breaths per minute, and body temperature changed by minus 0.03 degrees Celsius. Because the data as submitted does not include labels matching each specific blood test to its individual number, the full breakdown of which test corresponded to which figure was not able to be reported here. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 33157077) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must have previously enrolled in one of two specific related studies (called M10-877 or M10-880), and either reached what those studies called a "Treatment Failure" point, or fully completed one of those studies.
Who may not be able to join:
- You left the previous related study (M10-877 or M10-880) for any reason other than reaching a "Treatment Failure" event.
- You have cloudiness in the lens or cornea of your eye that blocks a clear view of the back of your eye, or that may require cataract surgery during the trial.
- You have high pressure inside your eye (25 mmHg or above) and are already taking two or more eye-pressure-lowering medications, or you show signs of eye nerve damage related to glaucoma.
- You have a serious form of diabetic eye disease (either a severe type or one causing significant swelling at the centre of your vision).
- You have the "wet" form of age-related macular degeneration (a condition causing abnormal blood vessel growth at the back of the eye).
- You have an abnormality at the point where the gel inside your eye meets the retina (such as pulling or scarring) that could damage your central vision on its own, separate from any inflammation (confirm with trial site).
- You have a whole-body inflammatory condition that requires you to take certain immune-suppressing medications that are not allowed in this trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Primary endpoints
Number of Participants With Adverse Events; Hematology: Number of Participants With Potentially Clinically Significant (PCS) Values; Chemistry: Number of Participants With PCS Values; Pulse (Sitting): Mean Change (Beats Per Minute) From Baseline To Final Visit; Respiratory Rate (Sitting): Mean Change (Respirations Per Minute) From Baseline To Final Visit; Temperature (Sitting): Mean Change (Centigrade) From Baseline To Final Visit; Diastolic and Systolic Blood Pressure (Sitting): Mean Change (mmHg) From Baseline To Final Visit
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.